Long-term neurocognitive outcomes of HIV-exposed uninfected children
暴露于艾滋病毒的未感染儿童的长期神经认知结果
基本信息
- 批准号:10633835
- 负责人:
- 金额:$ 63.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Every year, over a million children HIV-exposed but uninfected (CHEU) are born in sub-Saharan Africa and this
population will continue to increase with improving availability of antiretroviral therapy (ART). The long-term
effects of in utero exposure to HIV and ART on child health and well-being have not been adequately
characterized, especially in resource-limited settings. CHEU are at higher risk for infectious diseases and recent
studies suggest they may have impaired neurocognitive development compared to their children without HIV
exposure. Identifying the causes of and risk factors for neurocognitive delay is essential for the development of
effective interventions to improve the lives of CHEU children. This proposal takes advantage of the unique
opportunity to evaluate the impact of in utero HIV and ART exposure on neurocognitive development in children
by extending the cohort enrolled in an ongoing clinical study we are conducting in Malawi. We are screening
pregnant women, enrolling infants and conducting intensive analysis of neonatal adaptive immunity among
infants in three categories: (1) CHEU born to women diagnosed with HIV at the first antenatal visit, thus exposed
to uncontrolled viremia for at least half of gestation; (2) CHEU born to women initiated on ART prior to conception
with undetectable viral loads; and (3) infants born to HIV uninfected mothers. In this proposal, we will continue
enrollment into our cohort of CHEU and children without HIV exposure to reach the sample size required to
conduct a robust longitudinal analysis of neurocognitive outcomes. We will adapt standardized and locally
validated assessment tools to investigate overall neurodevelopment as well as key neurocognitive domains.
After our initial milestones are achieved, we propose to evaluate neurocognitive development at 18, 36, and 60
months of age. Our interdisciplinary study team of infectious disease specialists, developmental pediatricians,
psychologists and immunologists will lead one of the most comprehensive studies of CHEU in resource-limited
settings to simultaneously address the impact of maternal and neonatal factors on neurocognitive development
on this population. We hypothesize that in utero exposure to HIV will impair neurocognitive development in the
first five years of life and children born to HIV-infected mothers with untreated HIV infection at the start of
pregnancy will demonstrate more delay than children of mothers with undetectable HIV viral load throughout
pregnancy. We further hypothesize that immunological status at birth will contribute to impaired neurocognitive
development in HEU children and explore the possibility that basic maternal history or laboratory tests may
identify the highest risk infants. The results of this study can immediately be translated into interventions to
improve the lives of CHEU, especially in low-resource settings.
每年,在撒哈拉以南非洲出生的儿童中有100多万人感染艾滋病毒,但未受感染,
随着抗逆转录病毒疗法(ART)可获得性的改善,艾滋病患者人数将继续增加。长期
子宫内暴露于艾滋病毒和抗逆转录病毒疗法对儿童健康和福祉的影响尚未得到充分研究。
特别是在资源有限的情况下。CHEU感染传染病的风险较高,
研究表明,与没有艾滋病毒的孩子相比,他们的神经认知发育可能受损
exposure.确定神经认知延迟的原因和风险因素对于发展神经认知延迟至关重要。
采取有效干预措施,改善CHEU儿童的生活。该提案利用了独特的
有机会评估宫内HIV和ART暴露对儿童神经认知发育的影响
我们正在马拉维进行一项正在进行的临床研究,我们在筛选
孕妇,登记婴儿和进行密集的新生儿适应性免疫分析,
以下三类婴儿:(1)首次产前检查时被诊断感染艾滋病毒的妇女所生的CHEU,
不受控制的病毒血症至少一半的妊娠;(2)CHEU出生的妇女开始抗逆转录病毒治疗怀孕前
检测不到病毒载量;(3)未感染HIV的母亲所生婴儿。在这一建议中,我们将继续
入组我们的CHEU队列和没有HIV暴露的儿童,以达到所需的样本量,
对神经认知结果进行强有力的纵向分析。我们将适应标准化和本地化
经过验证的评估工具,以调查整体神经发育以及关键的神经认知领域。
在我们达到最初的里程碑后,我们建议在18岁、36岁和60岁时评估神经认知发展
月龄。我们的跨学科研究团队由传染病专家,发育儿科医生,
心理学家和免疫学家将领导一个最全面的研究CHEU在资源有限的
同时解决母体和新生儿因素对神经认知发育的影响
在这个人口。我们假设子宫内接触艾滋病毒会损害婴儿的神经认知发育
艾滋病毒感染母亲在出生后五年内未接受艾滋病毒感染治疗的情况
怀孕将显示出更多的延迟比儿童的母亲与检测不到艾滋病毒载量的整个
怀孕我们进一步假设,出生时的免疫状态将导致神经认知功能受损,
高浓缩铀儿童的发展,并探讨基本的母亲病史或实验室检查可能
找出高危婴儿。这项研究的结果可以立即转化为干预措施,
改善CHEU的生活,特别是在低资源环境中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melissa Gladstone其他文献
Melissa Gladstone的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melissa Gladstone', 18)}}的其他基金
Neurocognitive development of HIV-exposed and uninfected infants in Malawi
马拉维暴露于艾滋病毒和未感染艾滋病毒的婴儿的神经认知发育
- 批准号:
10483566 - 财政年份:2022
- 资助金额:
$ 63.97万 - 项目类别:
Long-term neurocognitive outcomes of HIV-exposed uninfected children
暴露于艾滋病毒的未感染儿童的长期神经认知结果
- 批准号:
10656585 - 财政年份:2022
- 资助金额:
$ 63.97万 - 项目类别:
Neurocognitive development of HIV-exposed and uninfected infants in Malawi
马拉维暴露于艾滋病毒和未感染艾滋病毒的婴儿的神经认知发育
- 批准号:
10620260 - 财政年份:2020
- 资助金额:
$ 63.97万 - 项目类别:
Neurocognitive development of HIV-exposed and uninfected infants in Malawi
马拉维暴露于艾滋病毒和未感染艾滋病毒的婴儿的神经认知发育
- 批准号:
10081039 - 财政年份:2020
- 资助金额:
$ 63.97万 - 项目类别:
Neurocognitive development of HIV-exposed and uninfected infants in Malawi
马拉维暴露于艾滋病毒和未感染艾滋病毒的婴儿的神经认知发育
- 批准号:
10227799 - 财政年份:2020
- 资助金额:
$ 63.97万 - 项目类别:
Neurocognitive development of HIV-exposed and uninfected infants in Malawi
马拉维暴露于艾滋病毒和未感染艾滋病毒的婴儿的神经认知发育
- 批准号:
10424474 - 财政年份:2020
- 资助金额:
$ 63.97万 - 项目类别:
Long-term neurocognitive outcomes of HIV-exposed uninfected children
暴露于艾滋病毒的未感染儿童的长期神经认知结果
- 批准号:
10063378 - 财政年份:2020
- 资助金额:
$ 63.97万 - 项目类别:
相似国自然基金
区域碳交易试点的运行机制及其经济影响研究---基于Term-Co2模型
- 批准号:71473242
- 批准年份:2014
- 资助金额:59.0 万元
- 项目类别:面上项目
长期间歇性缺氧抑制呼吸运动神经长时程易化的分子机制
- 批准号:81141002
- 批准年份:2011
- 资助金额:10.0 万元
- 项目类别:专项基金项目
激活γ-分泌酶促进海马长时程增强形成的机制
- 批准号:30500149
- 批准年份:2005
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Cognitive aging in long-term breast cancer survivors
长期乳腺癌幸存者的认知衰老
- 批准号:
10566264 - 财政年份:2023
- 资助金额:
$ 63.97万 - 项目类别:
Long-Term Effects of COVID-19 on Cognitive Function and Mental Health
COVID-19 对认知功能和心理健康的长期影响
- 批准号:
10703171 - 财政年份:2023
- 资助金额:
$ 63.97万 - 项目类别:
Delirium, Long-Term Cognition and the Dementia Pathological Trajectory
谵妄、长期认知和痴呆病理轨迹
- 批准号:
10574994 - 财政年份:2023
- 资助金额:
$ 63.97万 - 项目类别:
Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy
CAR-T 细胞治疗后神经毒性和长期结果的脑成像标志物
- 批准号:
10657106 - 财政年份:2023
- 资助金额:
$ 63.97万 - 项目类别:
Mechanisms and prediction of perioperative brain injury and its long-term impact: the NeuroVISION-2 biobank initiative.
围手术期脑损伤的机制和预测及其长期影响:NeuroVISION-2 生物库计划。
- 批准号:
486722 - 财政年份:2023
- 资助金额:
$ 63.97万 - 项目类别:
Operating Grants
Long-term microglia-targeted endogenous retrovirus-like particle (ERVLP) delivery of Cas12f editor to cure HIV
长期小胶质细胞靶向内源性逆转录病毒样颗粒 (ERVLP) 递送 Cas12f 编辑器以治愈 HIV
- 批准号:
10523246 - 财政年份:2022
- 资助金额:
$ 63.97万 - 项目类别:
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)
乳腺癌幸存者的超长期神经认知结果(ProbC2)
- 批准号:
10558447 - 财政年份:2022
- 资助金额:
$ 63.97万 - 项目类别:
Evaluating the Long-term Health Consequences of COVID-19 and Rehabilitation Therapies to Speed Convalescence
评估 COVID-19 的长期健康影响和加速康复的康复治疗
- 批准号:
10684750 - 财政年份:2022
- 资助金额:
$ 63.97万 - 项目类别:
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors (ProbC2)
乳腺癌幸存者的超长期神经认知结果(ProbC2)
- 批准号:
10643569 - 财政年份:2022
- 资助金额:
$ 63.97万 - 项目类别:
Neurovascular Uncoupling and Cognitive Impairments of Long COVID in Aging
衰老过程中长新冠病毒的神经血管解偶联和认知障碍
- 批准号:
10537136 - 财政年份:2022
- 资助金额:
$ 63.97万 - 项目类别: